AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Disease and Elevated Amyloid (A45 Trial) and in Subjects With E

Project: Research project

Project Details

Effective start/end date1/1/2012/31/23


  • University of Southern California (Subk No. 131741611)
  • Eisai, Inc. (Subk No. 131741611)